Avapritinib, sold under the brand name Ayvakit among others, is a medication used for the treatment of advanced systemic mastocytosis and indolent systemic mastocytosis. From Wikipedia
The deal carries a 27% premium and secures approved therapy Avapritinib plus early-stage immunology candidates under potentially $9.5 billion in milestone payments, preserving Sanofi’s 2025 outlook.
